Frias Joana, Martins Miguel, Peixoto Armando, Macedo Guilherme
Department of Gastroenterology, São João University Hospital, Porto, Portugal.
WGO Gastroenterology and Hepatology Training Center, Porto, Portugal.
GE Port J Gastroenterol. 2025 Apr 21:1-15. doi: 10.1159/000545926.
The gastrointestinal microbiota is vital for a well-functioning digestive tract, nutrient metabolism, immune support, and protection against pathogenic microorganisms. Disruption of this balance is known as dysbiosis. Rifaximin, an oral antibiotic with selective action, reduces harmful gut bacteria while preserving beneficial species, aiding in microbiota restoration.
Alterations in the intestinal microbiota are implicated in many gastrointestinal disorders. Rifaximin, by targeting and modulating the microbiota, may serve as a powerful tool in the approach of these conditions.
This narrative review summarizes the main uses of rifaximin in gastrointestinal disorders like irritable bowel syndrome, diverticular disease, small intestinal bacterial overgrowth, traveler's diarrhea, hepatic encephalopathy, infection, and inflammatory bowel disease.
胃肠道微生物群对于正常运作的消化道、营养代谢、免疫支持以及抵御病原微生物至关重要。这种平衡的破坏被称为生态失调。利福昔明是一种具有选择性作用的口服抗生素，可减少有害肠道细菌，同时保留有益菌种，有助于微生物群的恢复。
肠道微生物群的改变与许多胃肠道疾病有关。利福昔明通过靶向和调节微生物群，可能成为治疗这些疾病的有力工具。
本叙述性综述总结了利福昔明在胃肠道疾病中的主要用途，如肠易激综合征、憩室病、小肠细菌过度生长、旅行者腹泻、肝性脑病、感染和炎症性肠病。
